H.C. Wainwright initiated coverage of FibroBiologics (FBLG) with a Buy rating and $12 price target FibroBiologics is a clinical stage biotechnology company focused on development of fibroblast cellular therapies for chronic diseases, the analyst tells investors in a research note. The firm says the company’s “extensive” U.S. and international patent portfolio includes broad potential fibroblast cellular applications that include wound healing, disc degeneration, multiple sclerosis, orthopedics, psoriasis, reversing organ involution, and cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Announces Leadership Changes and New Appointments
- FibroBiologics announces updates for novel artificial thymus organoid technology
- FibroBiologics, Charles River establish master services agreement
- FibroBiologics issued patent for fibroblast delivery of tumor inhibitory agents
- Maxim starts FibroBiologics at Buy, sees fibroblast therapy as ‘more potent’